Merge pull request #2270 from EBISPOT/2235

Added sequencer terms for #2235
EBISPOT · Aug 8, 2024 · e1d02c8 · e1d02c8
2 parents 7fd121a + ae2685c
commit e1d02c8
Showing 1 changed file with 18 additions and 0 deletions.
diff --git a/src/ontology/efo-edit.owl b/src/ontology/efo-edit.owl
@@ -17223,6 +17223,8 @@ Declaration(Class(efo:EFO_0022836))
 Declaration(Class(efo:EFO_0022837))
 Declaration(Class(efo:EFO_0022838))
 Declaration(Class(efo:EFO_0022839))
+Declaration(Class(efo:EFO_0022840))
+Declaration(Class(efo:EFO_0022841))
 Declaration(Class(efo:EFO_0030000))
 Declaration(Class(efo:EFO_0030001))
 Declaration(Class(efo:EFO_0030002))
@@ -207549,6 +207551,22 @@ AnnotationAssertion(rdfs:label efo:EFO_0022839 "STORM-seq"@en)
 SubClassOf(efo:EFO_0022839 efo:EFO_0001457)
 SubClassOf(efo:EFO_0022839 efo:EFO_0010184)
 
+# Class: efo:EFO_0022840 (Illumina NovaSeq X)
+
+AnnotationAssertion(obo:IAO_0000115 efo:EFO_0022840 "The Illumina NovaSeq X is a high-throughput sequencing machine developed by Illumina.")
+AnnotationAssertion(dc:creator efo:EFO_0022840 "Zoe May Pendlington")
+AnnotationAssertion(dc:date efo:EFO_0022840 "2024-08-08T13:01:38Z"^^xsd:dateTime)
+AnnotationAssertion(rdfs:label efo:EFO_0022840 "Illumina NovaSeq X"@en)
+SubClassOf(efo:EFO_0022840 efo:EFO_0002699)
+
+# Class: efo:EFO_0022841 (Illumina NovaSeq X Plus)
+
+AnnotationAssertion(obo:IAO_0000115 efo:EFO_0022841 "The Illumina NovaSeq X Plus is a high-throughput sequencing machine developed by Illumina.")
+AnnotationAssertion(dc:creator efo:EFO_0022841 "Zoe May Pendlington")
+AnnotationAssertion(dc:date efo:EFO_0022841 "2024-08-08T13:10:10Z"^^xsd:dateTime)
+AnnotationAssertion(rdfs:label efo:EFO_0022841 "Illumina NovaSeq X Plus"@en)
+SubClassOf(efo:EFO_0022841 efo:EFO_0002699)
+
 # Class: efo:EFO_0030000 (STARmap)
 
 AnnotationAssertion(Annotation(oboInOwl:hasDbXref "PMID:29930089") Annotation(oboInOwl:hasDbXref "https://orcid.org/0000-0002-3090-9894") obo:IAO_0000115 efo:EFO_0030000 "STARmap is an image-based technology for 3D intact-tissue RNA sequencing, which integrates hydrogel-tissue chemistry, targeted signal amplification, and in situ sequencing.")